August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
April 2025 in “International Journal of Dermatology” Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
9 citations
,
January 2024 in “International Journal of Dermatology”
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
November 2015 in “Ankara Medical Journal” Weekly 5 mg folate is enough to prevent methotrexate toxicity in rheumatoid arthritis patients.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” Fisetin may help treat psoriasis and reduce skin inflammation.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
December 2025 in “Pediatric Dermatology” Trametinib can cause skin issues, but they can often be managed without stopping the drug.
1 citations
,
November 2022 in “International journal of trichology” A girl with a rare skin condition improved after one month of treatment with acitretin.
1 citations
,
July 2021 in “Current nanomedicine” The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.